An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment S Drożdżal, J Rosik, K Lechowicz, F Machaj, B Szostak, J Przybyciński, ... Drug Resistance Updates 59, 100794, 2021 | 279 | 2021 |
Betulin and its derivatives as novel compounds with different pharmacological effects S Amiri, S Dastghaib, M Ahmadi, P Mehrbod, F Khadem, H Behrouj, ... Biotechnology advances 38, 107409, 2020 | 229 | 2020 |
COVID-19: The Potential Treatment of Pulmonary Fibrosis Associated with SARS-CoV-2 Infection K Lechowicz, S Drożdżal, F Machaj, J Rosik, B Szostak, ... Journal of Clinical Medicine 9 (6), 1917, 2020 | 218 | 2020 |
FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy S Drożdżal, J Rosik, K Lechowicz, F Machaj, K Kotfis, S Ghavami, MJ Łos Drug resistance updates 53, 100719, 2020 | 189 | 2020 |
Pleiotropic effects of statins: A focus on cancer M Ahmadi, S Amiri, S Pecic, F Machaj, J Rosik, MJ Łos, J Alizadeh, ... Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1866 (12), 165968, 2020 | 131 | 2020 |
Aspirin and its pleiotropic application J Hybiak, I Broniarek, G Kiryczyński, LD Los, J Rosik, F Machaj, ... European journal of pharmacology 866, 172762, 2020 | 105 | 2020 |
Role of PFKFB3 and PFKFB4 in Cancer: Genetic Basis, Impact on Disease Development/Progression, and Potential as Therapeutic Targets K Kotowski, J Rosik, F Machaj, S Supplitt, D Wiczew, K Jabłońska, ... Cancers 13 (4), 909, 2021 | 100 | 2021 |
COVID-19: Pain Management in Patients with SARS-CoV-2 Infection—Molecular Mechanisms, Challenges, and Perspectives S Drożdżal, J Rosik, K Lechowicz, F Machaj, B Szostak, P Majewski, ... Brain Sciences 10 (7), 465, 2020 | 91 | 2020 |
Kidney damage from nonsteroidal anti‐inflammatory drugs—Myth or truth? Review of selected literature S Drożdżal, K Lechowicz, B Szostak, J Rosik, K Kotfis, ... Pharmacology Research & Perspectives 9 (4), e00817, 2021 | 72 | 2021 |
The role of genetics and epigenetics in the pathogenesis of gestational diabetes mellitus J Rosik, B Szostak, F Machaj, A Pawlik Annals of Human Genetics 84 (2), 114-124, 2020 | 69 | 2020 |
New therapies for the treatment of heart failure: a summary of recent accomplishments F Machaj, E Dembowska, J Rosik, B Szostak, M Mazurek-Mochol, ... Therapeutics and clinical risk management, 147-155, 2019 | 55 | 2019 |
COVID-19: The Influence of ACE Genotype and ACE-I and ARBs on the Course of SARS-CoV-2 Infection in Elderly Patients J Sieńko, M Kotowski, A Bogacz, K Lechowicz, S Drożdżal, J Rosik, ... Clinical Interventions in Aging 15, 1231, 2020 | 42 | 2020 |
The Role of the Human Microbiome in the Pathogenesis of Pain K Ustianowska, Ł Ustianowski, F Machaj, A Gorący, J Rosik, B Szostak, ... International Journal of Molecular Sciences 23 (21), 13267, 2022 | 37 | 2022 |
CTLA4 antagonists in phase I and phase II clinical trials, current status and future perspectives for cancer therapy B Szostak, F Machaj, J Rosik, A Pawlik Expert opinion on investigational drugs 28 (2), 149-159, 2019 | 30 | 2019 |
Using pharmacogenetics to predict methotrexate response in rheumatoid arthritis patients B Szostak, F Machaj, J Rosik, A Pawlik Expert Opinion on Drug Metabolism & Toxicology 16 (7), 617-626, 2020 | 29 | 2020 |
Potential targets of gene therapy in the treatment of heart failure J Rosik, B Szostak, F Machaj, A Pawlik Expert opinion on therapeutic targets 22 (9), 811-816, 2018 | 21 | 2018 |
Rhabdomyosarcoma: Current Therapy, Challenges, and Future Approaches to Treatment Strategies A Zarrabi, D Perrin, M Kavoosi, M Sommer, S Sezen, P Mehrbod, ... Cancers 15 (21), 5269, 2023 | 17 | 2023 |
The Role of BiP and the IRE1α–XBP1 Axis in Rhabdomyosarcoma Pathology M Aghaei, A Nasimian, M Rahmati, P Kawalec, F Machaj, J Rosik, ... Cancers 13 (19), 4927, 2021 | 13 | 2021 |
Reprogramming and transdifferentiation-two key processes for regenerative medicine J Hybiak, K Jankowska, F Machaj, J Rosik, I Broniarek, A Żyluk, ... European Journal of Pharmacology 882, 173202, 2020 | 13 | 2020 |
The evolution in our understanding of the genetics of rheumatoid arthritis and the impact on novel drug discovery F Machaj, J Rosik, B Szostak, A Pawlik Expert opinion on drug discovery 15 (1), 85-99, 2020 | 12 | 2020 |